HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Arora, S. Articles by Lin, C.-c. Search for Related Content PubMed PubMed Citation Articles by Arora, S. Articles by Lin, C.-c. Social Bookmarking                         What's this?

Ascending Multiple-Dose Pharmacokinetics of Viramidine, a Prodrug of Ribavirin, in Adult Subjects With Compensated Hepatitis C Infection

From Research and Development, Valeant Pharmaceuticals International, Costa Mesa, California (Dr Lin, Dr Xu, Ms Teng, Ms Peterson, Dr Yeh); University of New Mexico Health Science Center, Albuquerque, New Mexico (Dr Arora); California Pacific Medical Center, San Francisco (Dr Gish); University of Texas Medical Branch–Galveston, Galveston, Texas (Dr Lau); San Francisco Veterans Administration Medical Center, San Francisco, California (Dr Rossi).

The current study was carried out to evaluate pharmacokinetic profiles of viramidine and ribavirin in patients (n = 8 per dose group) with compensated hepatitis C infection following oral dosing of viramidine (400, 600, or 800 mg bid for 4 weeks). Pharmacokinetic parameters were determined on days 1 and 29 based on plasma, red blood cell, and urine concentrations of viramidine and ribavirin. The results indicate rapid absorption and conversion of viramidine to ribavirin after oral administration of viramidine. Viramidine and ribavirin exposure in plasma and RBCs generally increased from the 400- to 600-mg dose level of viramidine. However, no further increase in exposure was noted at the 800-mg dose. Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted. A negligible amount of viramidine (1%-4% of dose) and a small amount of ribavirin (9%-14% of dose) were excreted in the urine. The renal clearance was low for both viramidine (5-8 L/h) and ribavirin (4-7 L/h). Significant accumulation of viramidine was noted in red blood cells (accumulation factor [R] = 5-8) but not in plasma (R = 2). Extensive accumulation of ribavirin was noted in both plasma (R = 9-17) and red blood cells (R = 77-129). Steady-state levels of ribavirin and viramidine in plasma and red blood cells were achieved by day 22. At steady state, there was extensive conversion of viramidine to ribavirin in both plasma and red blood cells. Both viramidine and ribavirin were preferentially distributed into red blood cells than plasma.

Key Words: Viramidine • ribavirin • hepatitis C • pharmacokinetics

Address for reprints: Dr Chin-chung Lin, Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, CA 92626.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C.-c. Lin, C. Xu, N. Zhu, and L.-T. Yeh Absorption, Metabolism, and Excretion of [14C]Viramidine in Humans Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2368 - 2373. [Abstract] [Full Text] [PDF]